Although the specific mechanisms by which SLC16A11 plays a role in T2D risk and progression have not yet been fully elucidated, the evidence of its clinical impact on T2D warrants further experimental investigation while also potentially providing new ideas for other metabolic diseases. This evidence concerns the gene SLC16A11 and type 2 diabetes mellitus.